BRIEF-GSK CEO Says Don't Need Nuvalent Deal To Achieve £40 Bln Sales Target

Nuvalent, Inc. Class A

NUVL

0.00

GlaxoSmithKline plc Sponsored ADR

GSK

0.00

June 9 (Reuters) - GSK plc GSK.L:

GSK CEO LUKE MIELS SAYS NUVALENT DEAL SIZE IS LARGER THAN USUAL BRACKET BECAUSE IT WAS "UNUSUAL" TO GET MULTIPLE PRODUCTS IN ONE DEAL
GSK CEO: WORKING TO OFFSET COST OF SERVICING THE DEBT FROM DEAL FINANCING- MEDIA CALL
GSK CEO: CONVINCED THAT THIS WAS A DEAL THAT WE NEEDED TO DO
GSK CEO: WE DON'T NEED THIS NUVALENT DEAL TO ACHIEVE £40 BILLION SALES TARGET BY 2031

Further company coverage: GSK.L

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.